309 related articles for article (PubMed ID: 10064603)
41. Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine.
Jiang MC; Lin JK; Chen SS
Biochem Biophys Res Commun; 1996 Sep; 226(1):1-7. PubMed ID: 8806583
[TBL] [Abstract][Full Text] [Related]
42. Retinoblastoma gene inhibits transactivation of HIV-LTR linked gene expression upon co-transfection in He La cells.
Prasad MV; Shanmugam G
Biochem Mol Biol Int; 1993 Jan; 29(1):57-62. PubMed ID: 8490568
[TBL] [Abstract][Full Text] [Related]
43. Human immunodeficiency virus 1 Tat stimulates transcription of the transforming growth factor alpha gene in an epidermal growth factor-dependent manner.
Nabell LM; Raja RH; Sayeski PP; Paterson AJ; Kudlow JE
Cell Growth Differ; 1994 Jan; 5(1):87-93. PubMed ID: 8123596
[TBL] [Abstract][Full Text] [Related]
44. Blocking of Tat-dependent HIV-1 RNA modification by an inhibitor of RNA polymerase II processivity.
Braddock M; Thorburn AM; Kingsman AJ; Kingsman SM
Nature; 1991 Apr; 350(6317):439-41. PubMed ID: 2011194
[TBL] [Abstract][Full Text] [Related]
45. Effects of the tat and nef gene products of human immunodeficiency virus type 1 (HIV-1) on transcription controlled by the HIV-1 long terminal repeat and on cell growth in macrophages.
Murphy KM; Sweet MJ; Ross IL; Hume DA
J Virol; 1993 Dec; 67(12):6956-64. PubMed ID: 8230418
[TBL] [Abstract][Full Text] [Related]
46. Molecular approaches to inhibit HIV-1 tat expression and functions.
Grossi MP; Caputo A; Zucchini S; Bozzini R; Marconi PC; Manservigi R; Barbanti-Brodano G; Balboni PG
Year Immunol; 1993; 7():199-204. PubMed ID: 8396820
[No Abstract] [Full Text] [Related]
47. Spt5 cooperates with human immunodeficiency virus type 1 Tat by preventing premature RNA release at terminator sequences.
Bourgeois CF; Kim YK; Churcher MJ; West MJ; Karn J
Mol Cell Biol; 2002 Feb; 22(4):1079-93. PubMed ID: 11809800
[TBL] [Abstract][Full Text] [Related]
48. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor.
Herrmann CH; Rice AP
J Virol; 1995 Mar; 69(3):1612-20. PubMed ID: 7853496
[TBL] [Abstract][Full Text] [Related]
49. Role of the human homolog of the yeast transcription factor SPT5 in HIV-1 Tat-activation.
Wu-Baer F; Lane WS; Gaynor RB
J Mol Biol; 1998 Mar; 277(2):179-97. PubMed ID: 9514752
[TBL] [Abstract][Full Text] [Related]
50. Transient induction of cyclin T1 during human macrophage differentiation regulates human immunodeficiency virus type 1 Tat transactivation function.
Liou LY; Herrmann CH; Rice AP
J Virol; 2002 Nov; 76(21):10579-87. PubMed ID: 12368300
[TBL] [Abstract][Full Text] [Related]
51. Enhanced activity of human G6PD promoter transfected in HeLa cells producing high levels of HIV-1 Tat.
Ursini MV; Lettieri T; Braddock M; Martini G
Virology; 1993 Sep; 196(1):338-43. PubMed ID: 8356804
[TBL] [Abstract][Full Text] [Related]
52. Basal and Tat-transactivated expression from the human immunodeficiency virus type 1 long terminal repeat in human placental trophoblast rules out promoter-enhancer activation as the partial block to viral replication.
Zachar V; Ebbesen P; Thomas RA; Zacharova V; Goustin AS
J Gen Virol; 1994 Jun; 75 ( Pt 6)():1461-8. PubMed ID: 8207411
[TBL] [Abstract][Full Text] [Related]
53. HDAC1/NFκB pathway is involved in curcumin inhibiting of Tat-mediated long terminal repeat transactivation.
Zhang HS; Ruan Z; Sang WW
J Cell Physiol; 2011 Dec; 226(12):3385-91. PubMed ID: 21344388
[TBL] [Abstract][Full Text] [Related]
54. Ribozyme targeting of HIV-1 LTR.
Ventura M; Wang P; Franck N; Saragosti S
Biochem Biophys Res Commun; 1994 Sep; 203(2):889-98. PubMed ID: 8093072
[TBL] [Abstract][Full Text] [Related]
55. Tat-induced lesions in transgenic mice do not correlate with the HIV-1 LTR transactivation.
Fergelot P; Molina T; Blanchet P; Grimber G; Duquenne O; Couton D; Zider A; Briand P; Cavard C
C R Acad Sci III; 1995 Mar; 318(3):329-37. PubMed ID: 7788501
[TBL] [Abstract][Full Text] [Related]
56. PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo.
Gold MO; Yang X; Herrmann CH; Rice AP
J Virol; 1998 May; 72(5):4448-53. PubMed ID: 9557739
[TBL] [Abstract][Full Text] [Related]
57. Activation of the transcription from the human immunodeficiency virus type 1 (HIV-1) long terminal repeat by autologous and heterologous cell-to-cell contact.
Faure E; Lecine P; Imbert J; Champion S
Cell Mol Biol (Noisy-le-grand); 1996 Sep; 42(6):811-23. PubMed ID: 8891348
[TBL] [Abstract][Full Text] [Related]
58. Increasing the ratio of PP2A core enzyme to holoenzyme inhibits Tat-stimulated HIV-1 transcription and virus production.
Ruediger R; Brewis N; Ohst K; Walter G
Virology; 1997 Nov; 238(2):432-43. PubMed ID: 9400615
[TBL] [Abstract][Full Text] [Related]
59. Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms.
Chang LJ; McNulty E; Martin M
J Virol; 1993 Feb; 67(2):743-52. PubMed ID: 8419644
[TBL] [Abstract][Full Text] [Related]
60. Stimulation of Tat-independent transcriptional processivity from the HIV-1 LTR promoter by matrix attachment regions.
Rampalli S; Kulkarni A; Kumar P; Mogare D; Galande S; Mitra D; Chattopadhyay S
Nucleic Acids Res; 2003 Jun; 31(12):3248-56. PubMed ID: 12799452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
